
    
      The CHEOPS study aims to confirm the clinical benefit of a combination of an anti-aromatase
      and metronomic chemotherapy treatment that would have the theoretical advantage of being well
      tolerated and more effective than chemotherapy alone even after an anti-aromatase therapy.
    
  